These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 31769886)

  • 1. Comparison of gastrointestinal adverse events with different doses of metformin in the treatment of elderly people with type 2 diabetes.
    Yuxin H; Cuiping J; Wen T; Jieyuzhen Q; Xiaoming T; Qin G; Haidong W; Jiao S; Zhijun B
    J Clin Pharm Ther; 2020 Jun; 45(3):470-476. PubMed ID: 31769886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.
    Huang Y; Sun J; Wang X; Tao X; Wang H; Tan W
    J Clin Pharm Ther; 2015 Aug; 40(4):461-5. PubMed ID: 26032654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus.
    Huang Y; Sun J; Wang X; Tao X; Wang H; Tan W
    Diabetes Technol Ther; 2015 Feb; 17(2):128-33. PubMed ID: 25391019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.
    Dujic T; Causevic A; Bego T; Malenica M; Velija-Asimi Z; Pearson ER; Semiz S
    Diabet Med; 2016 Apr; 33(4):511-4. PubMed ID: 26605869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
    Hameed M; Khan K; Salman S; Mehmood N
    J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of metformin in elderly type 2 diabetes].
    Hajime M; Okada Y; Mori H; Arao T; Tanaka Y
    J UOEH; 2013 Sep; 35(3):207-12. PubMed ID: 24077589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by
    Dawed AY; Zhou K; van Leeuwen N; Mahajan A; Robertson N; Koivula R; Elders PJM; Rauh SP; Jones AG; Holl RW; Stingl JC; Franks PW; McCarthy MI; 't Hart LM; Pearson ER;
    Diabetes Care; 2019 Jun; 42(6):1027-1033. PubMed ID: 30885951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
    Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
    Nabrdalik K; Skonieczna-Żydecka K; Irlik K; Hendel M; Kwiendacz H; Łoniewski I; Januszkiewicz K; Gumprecht J; Lip GYH
    Front Endocrinol (Lausanne); 2022; 13():975912. PubMed ID: 36187122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactic acidosis induced by metformin in a chronic hemodialysis patient with diabetes mellitus type 2.
    Altun E; Kaya B; Paydaş S; Sarıakçalı B; Karayaylalı I
    Hemodial Int; 2014 Apr; 18(2):529-31. PubMed ID: 24299454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
    Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
    Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.